SCHEMBL2759622

SCHEMBL2759622

COOOOC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17761661 0.94
SCHEMBL4608955 0.94
SCHEMBL12723987 0.94
SCHEMBL5374330 0.94
SCHEMBL15958873 0.94
SCHEMBL3295943 0.94
SCHEMBL4865350 0.88
SCHEMBL4868112 0.88
SCHEMBL9419750 0.88
SCHEMBL6064795 0.88

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119528713-A Synthesis method of nemonoxacin intermediate 2, 4-difluoro-3-methoxy-1-benzoic acid 浙江昌海制药有限公司 2025-02-28 CN claimed
CN-119528713-A Synthesis method of nemonoxacin intermediate 2, 4-difluoro-3-methoxy-1-benzoic acid 浙江昌海制药有限公司 2025-02-28 CN disclosed
EP-3167396-B1 IMMUNE RECOGNITION MOTIFS IOGENETICS LLC (US) 2024-01-17 EP disclosed
US-20230332334-A1 LIQUID CRYSTAL POLYESTER FIBERS AND METHOD FOR PRODUCING SAME KURARAY CO., LTD. (JP) 2023-10-19 US disclosed
US-11572508-B2 Non-linear surfactant POWDERMET, INC. (US) 2023-02-07 US disclosed
US-20220127534-A1 NON-LINEAR SURFACTANT POWDERMET, INC. 2022-04-28 US disclosed
US-11273422-B2 Non-linear surfactant POWDERMET, INC. (US) 2022-03-15 US disclosed
US-20210237013-A1 NON-LINEAR SURFACTANT POWDERMET, INC. 2021-08-05 US disclosed
US-20170362338-A1 GLYCAN-BASED ANTIBODY-DRUG CONJUGATES MERCK SHARP & DOHME CORP. (US) 2017-12-21 US disclosed
US-9782236-B2 Method and system for finding tooth features on a virtual three-dimensional model ORAMETRIX, INC. (US) 2017-10-10 US disclosed
US-7001601-B1 Ganglioside-KLH conjugate vaccine plus QS-21 SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2006-02-21 US disclosed
US-6967022-B1 Ganglioside-KLH conjugate vaccines plus QS-21 SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2005-11-22 US disclosed
US-6936253-B1 Ganglioside-KLH conjugate vaccines plus QS-21 SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2005-08-30 US disclosed
US-6916476-B1 Ganglioslide-KLH conjugate vaccine plus QS-21 SLOAN-KETTERING INSTITUTE FOR CANCER INSTITUTE (US) 2005-07-12 US disclosed
EP-1360963-A2 Ganglioside-KLH conjugate vaccines with QS-21 Sloan-Kettering Institute For Cancer Research (US) 2003-11-12 EP disclosed
EP-0680338-B1 GANGLIOSIDE-KLH CONJUGATE VACCINES WITH QS-21 SLOAN KETTERING INST CANCER (US) 2003-04-16 EP disclosed
EP-0680338-A4 GANGLIOSIDE-KLH CONJUGATE VACCINES WITH QS-21. SLOAN KETTERING INST CANCER (US) 1997-04-09 EP disclosed
EP-0684261-A2 Emulsion polymerisation inhibitor and suspension polymerisation method using the agent NIPPON SHOKUBAI CO., LTD. (JP) 1995-11-29 EP disclosed
EP-0680338-A1 GANGLIOSIDE-KLH CONJUGATE VACCINES WITH QS-21 Sloan-Kettering Institute For Cancer Research (US) 1995-11-08 EP disclosed
WO-1994016731-A1 GANGLIOSIDE-KLH CONJUGATE VACCINES WITH QS-21 SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1994-08-04 WO disclosed